{
    "clinical_study": {
        "@rank": "119361", 
        "arm_group": {
            "arm_group_label": "Adults with systemic lupus erythematosus (SLE)", 
            "description": "Subjects with SLE receiving ongoing stable SLE treatment"
        }, 
        "brief_summary": {
            "textblock": "This pooled analysis will assess data from the Phase 3 belimumab registration studies\n      BLISS-52 (aka BEL110752) and BLISS-76 (aka BEL110751). The analysis was pre-planned and\n      agreed prior to the unblinding of either study. The primary objective is to evaluate the\n      impact of belimumab treatment on a more severe subpopulation of systemic lupus erythematosus\n      (SLE) subjects from BLISS-52 and BLISS-76 to aid physicians and payers in decision making.\n      Subjects are from the modified Intent-to-Treat (ITT) population defined as randomized\n      subjects who received at least 1 dose of study agent.  This more severe subpopulation will\n      have renal, neurological, haematological, or cardiovascular/respiratory organ domain\n      involvement (as defined by a British Isles Lupus Assessment Group (BILAG) domain score of A,\n      B or C in at least one of the domains) at baseline AND anti-double-stranded deoxyribonucleic\n      acid (anti-dsDNA) positive (\u2265 30 IU/mL) at baseline OR low C3 and/or C4 complement relative\n      to the normal range at baseline."
        }, 
        "brief_title": "Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76", 
        "completion_date": {
            "#text": "November 2010", 
            "@type": "Actual"
        }, 
        "condition": "Systemic Lupus Erythematosus", 
        "condition_browse": {
            "mesh_term": "Lupus Erythematosus, Systemic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Eligible subjects for BLISS-52 and BLISS-76 included:\n\n          -  clinical diagnosis of systemic lupus erythematosus (SLE) according to the American\n             College of Rheumatology (ACR) criteria\n\n          -  \"active\" (systemic lupus erythematosus) SLE disease, defined as a safety of oestrogen\n             in lupus national assessment (SELENA) systemic lupus erythematosus disease activity\n             index (SLEDAI) disease activity score of at least 6 at screening\n\n          -  an unequivocally positive antinuclear antibodies (ANA) test result, from 2\n             independent time points within the study screening period or 1 positive historical\n             test result and 1 positive test result during the screening period. ANA test results\n             obtained in the screening period were only considered positive if the ANA titer \u2265\n             1:80 and/or anti-dsDNA serum antibody was \u2265 30 IU/mL\n\n          -  on a stable SLE treatment regimen for at least 30 days prior to Day 0, which\n             consisted of any of the following (alone or in combination): prednisone or equivalent\n             (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to\n             40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or\n             any immunosuppressive therapy (i.e., methotrexate, azathioprine, leflunomide, or\n             mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide,\n             6-mercaptopurine, or thalidomide).\n\n          -  Additional inclusion criteria for the purpose of this analysis: subpopulation of\n             patients from the pooled modified Intent-to-Treat population from BLISS-52 and\n             BLISS-76 who have renal, neurological, haematological, or cardiovascular/respiratory\n             organ domain involvement (as defined by a BILAG domain score of A, B or C in at least\n             one of the domains) at baseline and 1 of the following:\n\n               -  are anti-dsDNA positive (\u2265 30 IU/mL) at baseline, OR\n\n               -  have low C3 and/or C4 complement relative to the normal range at baseline.\n\n        Exclusion Criteria:\n\n          -  Key exclusion criteria for BLISS-52 and BLISS-76 included:\n\n          -  severe active lupus nephritis or Central Nervous System (CNS) lupus\n\n          -  pregnancy\n\n          -  receipt of any B cell target therapy at any time\n\n          -  receipt of an investigational agent within 60 days prior to Day 0 for non-biologics\n             and within 1 year for biologics\n\n          -  receipt of abatacept (within 1 year), intravenous (IV) cyclophosphamide (within 6\n             months), anti-tumor necrosis factor (anti-TNF) therapy, anakinra, IV immunoglobulin\n             (IVIG), prednisone > 100 mg/day, or plasmapheresis within 3 months, or live vaccine\n             within 1 month."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The primary population is the subpopulation of patients from the pooled modified\n        Intent-to-Treat population from BLISS-52 and BLISS-76 who have renal, neurological,\n        haematological, or cardiovascular/respiratory organ domain involvement (as defined by a\n        BILAG domain score of A, B or C in at least one of the domains) at baseline and 1 of the\n        following:\n\n          -  are anti-double-stranded deoxyribonucleic acid (anti-dsDNA) positive (= 30 IU/mL) at\n             baseline, OR\n\n          -  have low C3 and/or C4 complement relative to the normal range at baseline."
            }
        }, 
        "enrollment": {
            "#text": "1016", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01914770", 
            "org_study_id": "114246"
        }, 
        "intervention": [
            {
                "arm_group_label": "Adults with systemic lupus erythematosus (SLE)", 
                "description": "Subjects received belimumab 1 mg/kg in addition to their ongoing stable systemic lupus erythematosus (SLE) treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).", 
                "intervention_name": "Belimumab 1 mg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Adults with systemic lupus erythematosus (SLE)", 
                "description": "Subjects received belimumab 10 mg/kg in addition to their ongoing stable SLE treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).", 
                "intervention_name": "Belimumab 10 mg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Adults with systemic lupus erythematosus (SLE)", 
                "description": "Subjects received placebo in addition to their ongoing stable SLE treatment regimen.  Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "pooled analyses", 
            "quality of life", 
            "SELENA SLEDAI", 
            "SLE", 
            "steroid use", 
            "responder rate", 
            "flares", 
            "belimumab", 
            "BILAG"
        ], 
        "lastchanged_date": "September 12, 2013", 
        "number_of_groups": "1", 
        "official_title": "Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Response is defined as: \u22654 point reduction from baseline in SELENA SLEDAI score, no worsening (increase of < 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores.", 
            "measure": "Responder Rate", 
            "safety_issue": "No", 
            "time_frame": "Week 52"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01914770"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percent of subjects with \u2265 4 point reduction from baseline in SELENA SLEDAI score at Week 52", 
                "measure": "SELENA SLEDAI", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "description": "Mean change in SF-36 Health Survey physical component summary score (PCS) at Week 24", 
                "measure": "SF-36", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Time to 1st SLE flare after 24 weeks by modified SLE Flare Index", 
                "measure": "Time to first flare by SLE Flare Index", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 52"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "collaborator": {
                "agency": "Human Genome Sciences Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2009", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}